Reports
Reports
Sale
The global anaesthesia drugs market stood at a value of nearly USD 6.08 billion in 2023. The market is further expected to grow at a CAGR of 4.2% in the forecast period of 2024-2032 to attain a value of almost USD 8.81 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of drug type, the local drug segment accounted for a significant share in the market and is anticipated to witness a steady growth over the forecast period. The growth can be attributed to the rising demand for local drugs in various applications, particularly dental surgeries. The anticipated increase in minor procedures such as filling or wisdom tooth removal is expected to bolster the demand for local anaesthetics. Meanwhile, the growing awareness about the benefits of general drugs, which include reduced intraoperative patient awareness and complete control of the airway, breathing and circulation, among others, is expected to aid the growth of the segment.
Based on the route of administration, the inhalation segment is likely to account for a significant share in the market owing to the cost-effectiveness of the method and its precise control over the anaesthetic state. Also, the inhaled anaesthetics have a low solubility in the blood and tissues, possess a protective effect and are resistant to physical and metabolic degradation, thus, further contributing to the demand growth.
North America, due to rapid technological advancements and the high healthcare expenditure, accounts for a considerable share in the market. The region is further expected to be aided by the increasing number of surgeries in countries like the United States and Canada. Meanwhile, Europe and the Asia Pacific are likely to grow at a significant rate in the forecast period owing to the ongoing healthcare reforms in the regions. The increasing focus to improve access to healthcare facilities in emerging countries of the Asia Pacific is expected to significantly contribute to the market growth in the forecast period.
Anaesthesia can be defined as the use of medicines to prevent pain during a medical procedure. Thus, the combination of medications that put a person in a sleep-like state before a surgery or some other medical procedure is known as anaesthetic drug. Anaesthetic drugs are used to ensure that a patient is in a completely unconscious state so that he/she does not feel any kind of pain.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on route of administration, the market is divided into:
On the basis of drug type, the industry is segmented into:
While the general drug segment is further divided into propofol, sevoflurane, desflurane, dexmedetomidine, remifentanil, midazolam, and others, the local drug segment is further categorised into bupivacaine, ropivacaine, lidocaine, chloroprocaine, prilocaine, benzocaine, and others.
The significant applications of the product are:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global anaesthesia drugs industry is driven by the rising prevalence of gastrointestinal diseases, such as gastroesophageal disease, liver cirrhosis, pancreatitis, and inflammatory bowel disease, among others. These diseases require intense surgery to attack the root of the disease, therefore, appropriate anaesthesia is needed for the safety of the patients. In addition, the easy availability of local drugs and the increasing hospitalisation rates are significantly contributing to the market growth. Over the forecast period, the market is expected to be aided by the rapid advancements in the healthcare industry.
The report gives a detailed analysis of the following key players in the global anaesthesia drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Route of Administration |
|
Breakup by Application |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Anaesthesia Drugs Market Overview
3.1 Global Anaesthesia Drugs Market Historical Value (2017-2023)
3.2 Global Anaesthesia Drugs Market Forecast Value (2024-2032)
4 Global Anaesthesia Drugs Market Landscape
4.1 Global Anaesthesia Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Anaesthesia Drugs Product Landscape
4.2.1 Analysis by Drug Type
4.2.2 Analysis by Route of Administration
4.2.3 Analysis by Applications
5 Global Anaesthesia Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Anaesthesia Drugs Market Segmentation
6.1 Global Anaesthesia Drugs Market by Type
6.1.1 Market Overview
6.1.2 General Anaesthesia Drugs
6.1.2.1 Propofol
6.1.2.2 Sevoflurane
6.1.2.3 Desflurane
6.1.2.4 Dexmedetomidine
6.1.2.5 Remifentanil
6.1.2.6 Midazolam
6.1.2.7 Others
6.1.3 Local Anaesthesia Drugs
6.1.3.1 Bupivacaine
6.1.3.2 Ropivacaine
6.1.3.3 Lidocaine
6.1.3.4 Chloroprocaine
6.1.3.5 Prilocaine
6.1.3.6 Benzocaine
6.1.3.7 Others
6.2 Global Anaesthesia Drugs Market by Route of Administration
6.2.1 Market Overview
6.2.2 Inhalation
6.2.3 Intravenous
6.2.4 Topical
6.3 Global Anaesthesia Drugs Market by Application
6.3.1 Market Overview
6.3.2 General Surgery
6.3.3 Heart Surgery
6.3.4 Plastic Surgery
6.3.5 Cosmetic Surgery
6.3.6 Dental Surgery
6.3.7 Hair Transplant Surgery
6.3.8 Other Applications
6.4 Global Anaesthesia Drugs Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Specialty Clinics
6.4.4 Dental Clinics
6.4.5 Ambulatory Surgical Centres
6.4.6 Others
6.5 Global Anaesthesia Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.4 Online Pharmacy
6.5.5 Others
6.6 Global Anaesthesia Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Anaesthesia Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Anaesthesia Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Anaesthesia Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Anaesthesia Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Anaesthesia Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Apotex Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Aspen Pharmacare Holdings Limited
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Baxter International Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Boehringer Ingelheim International GmbH
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Braun Melsungen AG
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Claris Lifesciences Limited
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Eisai Co. Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 F. Hoffmann-La Roche Ltd.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Fresenius SE & Co. KGaA
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Hikma Pharmaceuticals PLC
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Novartis AG
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Pacira Pharmaceuticals, Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Pfizer Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 Piramal Enterprises LTD.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 Septodont Healthcare India Pvt. Ltd.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
17.16 Teva Pharmaceutical Industries Limited
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisition
17.16.5 Certifications
17.17 Sanofi
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisition
17.17.5 Certifications
17.18 Takeda Pharmaceutical Company Limited
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisition
17.18.5 Certifications
18 Global Anaesthesia Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the global anaesthesia drugs market attained a volume of nearly USD 6.08 Billion.
The market is estimated to grow at a CAGR of 4.2% in the forecast period of 2024-2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 8.81 billion by 2032.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Inhalation, and injection, among others are the different routes of administration of the product.
General drug (propofol, sevoflurane, desflurane, dexmedetomidine, remifentanil, midazolam, and others) and local drug (bupivacaine, ropivacaine, lidocaine, chloroprocaine, prilocaine, benzocaine, and others) are the different drug types of the product.
General Surgery, Heart Surgerie, Plastic Surgery, Cosmetic Surgery, Dental Surgery and Hair Transplant Surgery, among others are the significant applications of the products.
The major players in the industry are F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Novartis AG, Pacira Pharmaceuticals, Inc., Pfizer Inc. and among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.